On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...